Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.
Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.
Hope for FDA authority over tobacco products dies in Congress.
Patients urge Medicare to allow an open formulary for cancer treatment.
Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.
Funding opportunities listed.
Trending Stories
- New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer” - ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications - Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?
- Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”
- NCI-designated Basic Laboratory Cancer Centers get research done—efficiently
- Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer